La agnostic therapy allows advancement of a tumor based on the tumor to a access based on biology and genomic alterations. I will start my sentence Jesús García Foncillas, Director of Instituto OncoHealth, a debate on ‘Personalized medicine and agnostic therapies’ marketed within the VI Liquid Biopsy Symposium.
The discovery of Genetic alterations is fully transforming the investigation and its translation into practice. The treatment is based exclusively on a molecular alteration, Independently of the type and location of the tumor is a reality in precision medicine. However, there is still an abatement of retreats and challenges that are not based on the diana organ, but that his therapies are strictly directed to a genetic profile.
In the field of agnostic therapies, the oncologist called them intratumoral genetic fusions . “We have disposable pharmaceuticals against NTRK (larotrectinib and entrectinib) with impressive results and a long duration of the response ”, said Foncillas.
The detection of Resistance mechanisms which, on occasions including the presence of mutations in the tyrosine quinine activity domain of this genetic fusion, has made it to a second generation of NTKR inhibitors actuating capacities for these resistance mutations: reprotectinib and selitrectinib.
Reprotectinib is a pharmacy that acts as an act against the cases NTKR also actuate front to Ros1 and ALK. “This means that we have an enormous number of different tumors in which we can identify these genetic fusions,” said the expert. For its part, selitrectinib is able to act in those NTKR cases with mutation in the tyrosine quinase activity domain.
Staff have also recorded that the mergers ALK can be detected in different types of tumors. “It was described as a cancer of my mother, corrective, of pulmon … We could detect it distinguishes mutations of resistance with the first generation of ALK “, the specialist pointed out.
In conclusion, Foncillas has resulted in the new paradigm of Oncology. “We have events like the genetic mergers that can be detected in the liquid biopsy. We will propose the best solutions for patients with cancer and the detection of these genetic events can be the basis for improving their lives ”, he concluded.
In this sense, Razelle Kurzrock, professor at the University of MD Anderson Cancer of Houston (Texas), who also participated in this month, welcomed the enthusiasm that provoked in a principle the dates that the NGS is proportionate. Sondeverbod, “The metastatic tumors in late stages are very complex and have many problems with those because they are different from them” continued the specialist. Hoy por hoy no tenemos que buskas aspits comunes entre los patients pore podemos analyzing la genomics una combination of drugs that attack the genomic alterations of this pharmacy ”, he added.